Clinical trial
A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome
NCT01725152 is registered in ClinicalTrials.gov with Marinus Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome
- Lead sponsor
- Marinus Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2012
- Completion date
- November 1, 2016
- Enrollment
- 59 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.